The incidences of prostate cancer (PC) and diabetes are increasing, with a sustained trend. The occurrence of PC and type 2 diabetes mellitus (T2DM) is growing with aging. The correlation between PC occurrence and diabetes is noteworthy, as T2DM is correlated with a reduced risk of incidence of prostate cancer. Despite this reduction, diabetes mellitus increases the mortality in many cancer types, including prostate cancer. The treatment of T2DM is based on lifestyle changes and pharmacological management. Current available drugs, except insulin, are aimed at increasing insulin secretion (sulfonylureas, incretin drugs), improving insulin sensitivity (biguanides, thiazolidinediones), or increasing urinary glucose excretion (gliflozin). Comorbidities should be taken into consideration during the treatment of T2DM. This review describes currently known information about the mechanism and impact of commonly used antidiabetic drugs on the incidence and progression of PC. Outcomes of pre-clinical studies are briefly presented and their correlations with available clinical trials have also been observed. Available reports and meta-analyses demonstrate that most anti-diabetic drugs do not increase the risk during the treatment of patients with PC. However, some reports show a potential advantage of treatment of T2DM with specific drugs. Based on clinical reports, use of metformin should be considered as a therapeutic option. Moreover, anticancer properties of metformin were augmented while combined with GLP-1 analogs.

Theranostics utilize ligands that chelate radionuclides and selectively bind with cancer-specific membrane antigens. In the case of prostate cancer (PCa), the state-of-the-art lutetium-177-PSMA combines the radioactive β-emitter ¹⁷⁷Lu with Vipivotide Tetraxetan, a prostate-specific membrane antigen (PSMA)-binding ligand. Several studies have been conducted, and the therapy is not without adverse effects (e.g., xerostomia, nausea, and fatigue); however, few events are reported as severe. The available evidence supports the use of ¹⁷⁷Lu-PSMA in selected metastatic castration-resistant prostate cancer patients, and the treatment is considered a standard of care in several clinical scenarios. Emerging research shows promising results in the setting of hormone-sensitive prostate cancer; however, evidence from high-quality controlled trials is still missing. In this review, we discuss the available evidence for the application of ¹⁷⁷Lu-PSMA in the management of PCa patients.

Wstęp: W celu oceny ogniska zakażenia Clostridioides difficile (Clostridioides difficile infection – CDI) w okresie od grudnia 2018 r. do lutego 2019 r. na oddziale chorób wewnętrznych szpitala powiatowego na Śląsku objęto badaniem materiały kliniczne od 5 pacjentów (6 stolców).Materiał i metody: Zidentyfikowano izolaty C. difficile, geny kodujące dehydrogenazę glutaminianową (GDH) – gluD, toksyny A/B – tcdA/tcdB oraz geny cdtA/cdtB kodujące toksynę binarną, ermB wykryto za pomocą mPCR, a antybiotykooporność za pomocą E-testów.Wyniki: Wśród pacjentów dominowały kobiety (4/5). Wszystkie szczepy C. difficile (6) należały do hiperepidemicznego rybotypu 027, we wszystkich szczepach wykazano obecność badanych genów oraz wykryto oporność na: moksyfloksacynę, erytromycynę, klindamycynę, ryfampicynę, imipenem i chloramfenikol.Wnioski: Uzyskane wyniki świadczą o szerzeniu się na oddziale hiperepidemicznego klonu C. difficile o rybotypie 027.